Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
October-2017 Volume 38 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
October-2017 Volume 38 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma

  • Authors:
    • Kangsong Tian
    • Wei Qi
    • Qian Yan
    • Feng Zhang
    • Delei Song
    • Haiyang Zhang
    • Ming Lv
  • View Affiliations / Copyright

    Affiliations: Trauma Department of Orthopedics, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China, Microscopic Department of Orthopedics, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China
  • Pages: 2335-2342
    |
    Published online on: August 22, 2017
       https://doi.org/10.3892/or.2017.5914
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Osteosarcoma is a common bone tumor which is affected by E2, the most representative estrogen. Gene regulation function of E2 is highly dependent on estrogen receptor. The purpose of this study was to explore the gene regulation patterns of E2 through estrogen receptor α (ESR1) in osteosarcoma based on the combined analysis of ChIP-seq and gene microarray. All of the datasets were downloaded from the Gene Expression Omnibus (GEO). Differential expression genes (DEGs) in E2 treated U2OS cells expressing ESR1 (U2OS-ERα) compared with those treated with vehicle were obtained based on R programming software. ESR1-specific binding sites (peaks) in E2 treated U2OS cells were identified through MACS. Overlaps between DEGs and ESR1 target genes which contained peaks in promoters were considered as reliable E2-mediated genes through ESR1 in osteosarcoma. Moreover, we conducted miRNA-Gene regulation analysis for those genes through miRWalk database to identify potential therapeutic targets for the genes. Functional enrichment analysis of DEGs indicated their potential involvement in cancer, and cell activity-related processes. Fifteen overlaps were identified between DEGs and target genes of ESR1, of which 12 were found to be regulated by miRNA. Several known estrogen response genes and novel genes were obtained in this study and they might provide potential therapeutic targets for osteosarcoma.

Introduction

ESR1, also known as ER-alpha or ERα, is an important estrogen receptor (ER) and involves in the gene regulation in various diseases and biological processes, including breast cancer (1,2), osteosarcoma (3) and cell growth (4). 17β-estradiol (E2) is one of the most representative estrogens responsible for the development and reproductive capability of female characteristics (5). Besides, it participates in the progression of many diseases, for example, E2 could regulate the proliferation of breast cancer cells through focal adhesion and chemokine signaling pathways (6); through autophagy and apoptosis pathways, E2 plays important roles in the regulation of renal cell carcinoma growth (7). Furthermore, ER, including ERα and ERβ, are important media through which E2 involves the regulation of many biological processes. So, exploration of interactions between ER and E2 would promote our understanding of many types of complex diseases and the identification of their potential therapeutic targets.

Osteosarcoma is one of the most common malignant neoplasms in children and adolescents with ~20% 5-year overall survival rate after chemotherapy (8–10). In primary osteosarcoma, adequate surgical margins could significantly improve the prognosis, whereas, it is still a challenging surgical technique (11). Moreover, metastasis greatly affects prognosis for osteosarcoma due to the propensity of early metastatic trend and ~80% of osteosarcoma patients have metastasis at diagnosis (12,13). Understanding its mechanisms and screening of potential biomarkers would be helpful for its early diagnosis and improvement of prognosis. The development of biotechnologies have promoted the identification of diagnosis and therapeutic targets for osteosarcoma. For example, microRNA-491-5p was considered to suppress cell proliferation and promote apoptosis via FOXP4 in the report of Yin et al (14) through the quantification of miR-491-5p expression and cell apoptosis; through immunohistochemistry and statistic analysis, Zhao et al (15) identified HIF1 as an independent prognostic biomarker in osteosarcoma; furthermore, Zhou et al (16) even indicated that the level of miR-199a-5p in serum/plasma might serve as biomarker for osteosarcoma.

Estrone and estriol, also known as E1 and E3, are another type of estrogens which have been proved to be involved in the progression of several diseases, including osteosarcoma. For example, Mochizuki et al proved that E3 is compatible with E2 to induce the expression of IGF-1 mRNA and then affect the proliferative potential of osteosarcoma cells (17). Besides, E1 sulfate represents the most abundant estrogen in circulation of adults and plays a role in human bone maturation and homeostasis (18), and it has been shown to influence the progression of many types of cancers, such as colorectal cancer (19) and breast cancer (20), so it might be also associated with the development of osteosarcoma.

There are also several studies on E2 and ESR1 in osteosarcoma (3,21,22). While, no study has focused on the genome binding profiles of ESR1 with the presence of E2 and the E2-regulated genes through ESR1 simultaneously. In this study, a combined analysis of ESR1 chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) with the presence of E2 and gene expression profiles of E2-regulated through ESR1 was conducted. This would induce several potential target genes of ESR1 in osteosarcoma, and here, the E2-regulated genes in balance. This would be helpful for the identification of E2 targeted molecules in osteosarcoma and the development of corresponding drugs.

Materials and methods

Genome binding and expression profile datasets

All of the datasets in this study were obtained from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). For the analysis of genome binding of ESR1, the data of Chen et al were used with the accession number of GSE26110 which contains the SRC-1 and ESR1 genome-wide binding profiles with or without the presence of E2 in U2OS osteosarcoma cells. Another dataset (GSE1153), deposited by Stossi et al (22) was composed of U2OS cells expressing ERα (ESR1) or ERβ and treated with vehicle or the same amount of E2 for 4, 8, 24 and 48 h, was used for the determination of E2 targeted genes. The transcriptome expression level of the samples were quantified via GPL91 [HG_U95A] Affymetrix Human Genome U95A Array, a commercial affymetrix gene microarray.

ChIP-seq data analysis

We first conducted quality control for the raw sequencing data in fastq with FastQC, a quality control tool for high-throughput sequence data. Bowtie 2 (23) was used for the fast and sensitive read alignment with the default parameters setting after the removal of reads with poor quality, i.e., length <20 and more than 3 bases with the quality score <20 in this study. After the removal of duplicate alignments, the binding sites, referred as peak hereafter, of ESR1 were identified via the Model-based Analysis for ChIP-seq (MACS) version 2 (24), a widely used peak caller for transcription factor and histone modifier developed by Feng et al. Finally, ChIPseeker (25) and deepTools (26) were used for the assignment of genomic features, such as gene ID and relative location to transcription start site (TSS) to the peaks and visualization of binding profiles of ESR1 respectively.

Microarray data analysis

Gene expression profile analysis mainly involved two steps, i.e., preprocessing and identification of differential expression genes (DEGs). Briefly, raw CEL data was imported to R software and normalized through affy package (27) and the expression value was logarithmically transformed based on 2 and summarized to gene level; the identification of DEGs was performed through limma package (28) with the thresholds of fold change >1.41 and Bonferroni adjusted P-value <0.05.

Functional enrichment analysis

To explore the functions involving DEGs, we performed functional enrichment analysis through the Database for Annotation, Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) (29). We considered Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways with P-value <0.05 and minimum gene hits >2 as significantly enriched.

miRNA-Gene network analysis

In this study, the overlaps between target genes of ESR1 in U2OS cells with the presence of E2 and DEGs in E2 treated U2OS cells with expressed ESR1 were considered E2-regulated genes through ESR1 in osteosarcoma. To further explore their roles in osteosarcoma, we performed miRNA-Gene regulation analysis through miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/) (30) and the regulation relationships were screened out only when they were found in four out of the miRanda, miRDB, miRWalk, RNA22 and TargetScan databases. Besides, Cytoscape (31), an open source platform for complex network analysis and visualization, was used for the presentation of miRNA-Gene network.

Results

ChIP-seq data analysis

Quality control indicated high quality reads suitable for the following analysis (Fig. 1A). Read alignments resulted in 88.76% (11,409,959 out of 12,854,413 reads) and 75.98% (9,744,663 out of 12,825,873 reads) overall alignment rate for the ChIP-seq data of ESR1 and IgG control, respectively. Through MACS, we obtained a total of 45,355 ESR1-specific binding peaks and their genomic distribution are shown in Fig. 1B. Moreover, 7,712 peaks were assigned to the promoters of 4,541 unique genes, i.e., up- and down-stream 3,000 bp surrounding the TSS, which were considered as the most confident target genes of ESR1 and abbreviated as PGenes in this study. Besides, significant enrichment of ESR1 binding peaks was obtained surrounding TSS of its target genes and shown in Fig. 1C.

Figure 1.

ChIP-seq analysis. (A) Quality score for raw ChIP-seq datasets. (B) Genomic distribution of ESR1-specific binding peaks. (C) ESR1 binding profiles surrounding the TSS of its target genes.

Microarray data analysis

Preprocessing step resulted in comparable overall expression values among all of the samples (Fig. 2A). DEGs in 4 h (DEG4), 8 h (DEG8), 24 h (DEG24) and 48 h (DEG48) E2 treated U2OS cells expressing ESR1 (U2OS-ERα) compared with U2OS-ERα treated with vehicle were obtained and cross analyzed. As a result, we identified 216, 240, 654 and 649 hits for DEG4, DEG8, DEG24 and DEG48, respectively, and 34 overlaps were also obtained (Fig. 2B). The 34 overlaps are shown in Table I. Fig. 2C illustrated the supervised two-way hierarchical clustering of the 34 overlaps and samples. As expected, 24 and 48 h E2 treated U2OS-ERα samples were clustered together and the 4 h, and 8 h treated, and vehicle treated U2OS-ERα were separately clustered in their own groups.

Figure 2.

Gene microarray analysis. (A) Relative mRNA level in every sample after normalization. (B) Overlaps among DEG4, DEG8, DEG24 and DEG48. (C) Supervised clustering of the 34 overlapped genes and samples.

Table I.

The 34 overlapped genes among DEG4, DEG8, DEG24 and DEG48.

Table I.

The 34 overlapped genes among DEG4, DEG8, DEG24 and DEG48.

Gene namelog2FC_DEG4log2FC_DEG8log2FC_DEG24log2FC_DEG48
ADCY82.682.312.361.62
CA121.121.461.381.37
CAMK1−0.72−0.64−0.75−0.87
ENPP20.690.770.750.87
F13A10.861.681.461.20
FBXO280.950.980.951.18
FCMR1.381.470.901.95
GREB10.801.351.421.50
GRK51.361.560.990.60
IFI35−1.18−0.54−1.13−0.94
IFI44L1.451.021.111.00
ITGA60.560.721.441.36
KRT191.222.464.104.08
LRIG11.141.271.221.12
MAN1A21.511.331.671.86
MYBL11.140.711.521.06
NAT9−0.66−0.76−1.08−1.05
NCAM11.170.810.930.92
NLRP31.321.311.380.99
NRIP10.750.611.091.34
NUP580.750.840.931.01
NUS1P30.610.730.780.87
PHTF11.902.032.172.11
PITX2−0.57−1.21−2.69−1.65
PRKX1.221.341.531.49
PTGS21.392.583.623.72
RET1.401.481.361.63
SLC30A10.700.711.171.20
SLC35A30.660.820.770.80
TACC10.580.670.891.09
TCN2−0.73−0.58−0.50−0.60
TMOD10.710.890.780.73
TRPM12.843.723.563.82
WNK10.630.710.630.73

[i] log2FC represents value of log2 transformed fold change.

Enriched functions

We identified 50, 44, 175 and 171 significantly enriched GO terms for DEG4, DEG8, DEG24 and DEG48, respectively. Most of the GO terms were closely related with the processes of cancer progression, cell adhesion, RNA binding and so on. Besides, several estrogen, cancer and inflammatory associated KEGG pathways were also obtained and shown in Fig. 3.

Figure 3.

Significantly enriched KEGG pathways of DEG4, DEG8, DEG24 and DEG48.

miRNA-Gene network

Cross analysis of PGenes and the 34 overlapped DEGs identified 15 overlaps, i.e., RET, TRPM1, CA12, KRT19, GREB1, F13A1, TACC1, LRIG1, ADCY8, TMOD1, SLC30A1, NLRP3, WNK1, ITGA6 and ENPP2. Three examples of ESR1 binding peaks in the promoter of ITGA6, SLC30A1 and WNK1 further confirmed their association with ESR1 (Fig. 4).

Figure 4.

ESR1 binding tracks in ITGA6, SLC30A1 and WNK1.

miRNA is a kind of non-coding RNA with the length of ~22 nt. It can regulate gene expression through preventing transcription or degradating protein. We further explored the miRNA-Gene regulation relationships of the 15 overlaps for the comprehensive understanding of gene regulation patterns in E2 treated U2OS-ERα cells. As a result, 12 out of the 15 overlaps except CA12, KRT19 and ADCY8 were found to be regulated by one or more miRNAs. Fig. 5 illustrates the miRNA-Gene regulation network.

Figure 5.

miRNA-Gene regulation network of the overlaps between the 34 overlapped DEGs and PGenes.

Discussion

Osteosarcoma is the most common bone tumor with high morbidity and mortality. E2 was found to play important roles in osteosarcoma through regulating physiological processes and gene expression via ESR1 by many studies (3,32). While, the combined analysis of E2-mediated gene expression and regulation is still limited. In this study, we conducted gene microarray and ChIP-seq analysis in E2 treated U2OS-ERα cell lines, which would be useful to promote our understanding of the E2-mediated gene regulation in osteosarcoma.

E2-activated ESR1 could directly or indirectly bind to its target genes and then regulate the particular biological processes or gene expression. In osteosarcoma, E2 is necessary for the translocation of ESR1 to the nuclei. For example, Hu et al showed that ESR1 could promote the binding of Sp1 to the promoter of MALAT1, a long non-coding RNA, in U2OS cells to affect physiological processes only with E2 stimulation (32); Tübel et al even proved that the methylation status of ESR1 was affected by E2 (3). In this study, the ChIP-seq analysis of E2 stimulated U2OS-ERα cell identified the potential target genes of E2 mediated through ESR1. Besides, cross analysis with gene microarray could further screen out more reliable target genes for osteosarcoma.

Functional enrichment analysis resulted in the identification of cancer, cell activity-related KEGG pathways, which further confirmed our results. Estrogen signaling pathway was found to be significantly enriched in DEG4 and DEG48, which indicated roles of E2 in the activation of ESR1.

E2 could also regulate the expression level of microRNA (miRNA) and affect cell proliferation, migration and invasion in osteosarcoma. In turn, E2-mediated genes might also be regulated by miRNA. In this study, we performed miRNA-Gene regulation analysis for overlaps between PGenes and overlapped genes among the four lists of DEGs. Finally, 12 out of the 15 overlaps were found to be regulated by miRNA and ACC1 with the highest degree. ACC1 could act as anti- and pro-apoptotic regulators which involves in several cellular activities, including embryonic development, homeostasis, and tumorigenesis. Besides, it has been proved as potential biomarker in many types of cancers, such as gliomas, and melanoma (33,34). Significant enrichment of ESR1-specific binding peaks were identified in the promoter of WNK1 (Fig. 4, bottom), which was regulated by 31 miRNAs in this study. WNK1 and ESR1 were found to have differential expression in osteoporosis simultaneously (35). GREB1 was found with differential expression in U2OS-ERα cells at 4, 8, 24 and 48 h after E2 treated and regulated by E2 through ESR1. Consistent with our study, Lin and Lei reported that GREB1 was a estrogen-responsive gene and with two canonical estrogen response elements (36).

In conclusion, this study identified the potential E2-mediated genes through ESR1 in osteosarcoma via the combined analysis of ChIP-seq and gene microarray analysis. It could be helpful for the identification of therapeutic targets for osteosarcoma.

Glossary

Abbreviations

Abbreviations:

GEO

Gene Expression Omnibus

DAVID

Database for Annotation, Visualization and Integrated Discovery

U2OS-ERα

U2OS cells expressing ESR1

miRNA

microRNA

E2

17β-estradiol

References

1 

Flodrova D, Toporova L, Macejova D, Lastovickova M, Brtko J and Bobalova J: A comparative study of protein patterns of human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. Gen Physiol Biophys. 35:387–392. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Li T, Zhao J, Yang J, Ma X, Dai Q, Huang H, Wang L and Liu P: A meta-analysis of the association between ESR1 genetic variants and the risk of breast cancer. PLoS One. 11:e01533142016. View Article : Google Scholar : PubMed/NCBI

3 

Tübel J, Kuntz L, Marthen C, Schmitt A, Wiest I, Von Eisenhart-Rothe R, Jeschke U and Burgkart R: Methylation of the ER-alpha promoter is influenced by its ligand estrogen in osteosarcoma cells SAOS-2 in vitro. Anticancer Res. 36:3199–3204. 2016.PubMed/NCBI

4 

Meng D, Li Z, Ma X, Fu L and Qin G: MicroRNA-1280 modulates cell growth and invasion of thyroid carcinoma through targeting estrogen receptor α. Cell Mol Biol (Noisy-le-grand). 62:1–6. 2016.

5 

Guo JJ, Yang DP, Tian X, Vemuri VK, Yin D, Li C, Duclos RI Jr, Shen L, Ma X, Janero DR, et al: 17β-estradiol (E2) in membranes: Orientation and dynamic properties. Biochim Biophys Acta. 1858:344–353. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Huan J, Wang L, Xing L, Qin X, Feng L, Pan X and Zhu L: Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2). Gene. 533:346–355. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Chen KC, Lin CM, Huang CJ, Chen SK, Wu ST, Chiang HS and Ku WC: Dual roles of 17-β estradiol in estrogen receptor-dependent growth inhibition in renal cell carcinoma. Cancer Genomics Proteomics. 13:219–230. 2016. View Article : Google Scholar : PubMed/NCBI

8 

He X, Gao Z, Xu H, Zhang Z and Fu P: A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes. J Orthop Surg. 12:52017. View Article : Google Scholar

9 

Zhang W, Han S and Sun K: Combined analysis of gene expression, miRNA expression and DNA methylation profiles of osteosarcoma. Oncol Rep. 37:1175–1181. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Ren W and Gu G: Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: A meta-analysis. Eur J Cancer Care (Engl). 27–October;2015.(Epub ahead of print). PubMed/NCBI

11 

Wang Y, Guo W, Shen D, Tang X, Yang Y, Ji T and Xu X: Surgical treatment of primary osteosarcoma of the sacrum: A case series of 26 patients. Spine. Dec 16–2016.(Epub ahead of print).

12 

Zhang Z, Wang F, Li Q, Zhang H, Cui Y, Ma C, Zhu J, Gu X and Sun Z: CD151 knockdown inhibits osteosarcoma metastasis through the GSK-3β/β-catenin/MMP9 pathway. Oncol Rep. 35:1764–1770. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Pu Y, Zhao F, Cai W, Meng X, Li Y and Cai S: MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively. Clin Exp Metastasis. 33:359–372. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Yin Z, Ding H, He E, Chen J and Li M: Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma. Cell Prolif. Oct 5–2016.(Epub ahead of print).

15 

Zhao H, Wu Y, Chen Y and Liu H: Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma. Int J Clin Oncol. 20:1233–1243. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Zhou G, Lu M, Chen J, Li C, Zhang J, Chen J, Shi X and Wu S: Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma. Tumour Biol. 36:8845–8852. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Mochizuki S, Yoshida S, Yamanaka Y, Matsuo H and Maruo T: Effects of estriol on proliferative activity and expression of insulin-like growth factor-I (IGF-I) and IGF-I receptor mRNA in cultured human osteoblast-like osteosarcoma cells. Gynecol Endocrinol. 20:6–12. 2005. View Article : Google Scholar : PubMed/NCBI

18 

Muir M, Romalo G, Wolf L, Elger W and Schweikert HU: Estrone sulfate is a major source of local estrogen formation in human bone. J Clin Endocrinol Metab. 89:4685–4692. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Gilligan LC, Gondal A, Tang V, Hussain MT, Arvaniti A, Hewitt AM and Foster PA: Estrone sulfate transport and steroid sulfatase activity in colorectal cancer: Implications for hormone replacement therapy. Front Pharmacol. 8:1032017. View Article : Google Scholar : PubMed/NCBI

20 

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, et al: Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat. 71:453–461. 2017. View Article : Google Scholar

21 

Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J and Li Y: 17β-estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating miR-9 and thus degrades MALAT-1 in osteosarcoma cell MG-63 in an estrogen receptor-independent manner. Biochem Biophys Res Commun. 457:500–506. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR and Katzenellenbogen BS: Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology. 145:3473–3486. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Langmead B and Salzberg SL: Fast gapped-read alignment with Bowtie 2. Nat Methods. 9:357–359. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Feng J, Liu T, Qin B, Zhang Y and Liu XS: Identifying ChIP-seq enrichment using MACS. Nat Protoc. 7:1728–1740. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Yu G, Wang LG and He QY: ChIPseeker: An R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 31:2382–2383. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Ramírez F, Dündar F, Diehl S, Grüning BA and Manke T: deepTools: A flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42W1:W187–W191. 2014. View Article : Google Scholar

27 

Gautier L, Cope L, Bolstad BM and Irizarry RA: affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Diboun I, Wernisch L, Orengo CA and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI

29 

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4:32003. View Article : Google Scholar

30 

Dweep H, Sticht C, Pandey P and Gretz N: miRWalk - Database: Prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI

32 

Hu Q, Li S, Chen C, Zhu M, Chen Y and Zhao Z: 17β-Estradiol treatment drives Sp1 to upregulate MALAT-1 expression and epigenetically affects physiological processes in U2OS cells. Mol Med Rep. 15:1335–1342. 2017. View Article : Google Scholar : PubMed/NCBI

33 

You G, Feng L, Yan W, Zhang W, Wang YZ, Li SW, Li SW, Li GL, Song YJ, Kang CS, et al: BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas. CNS Neurosci Ther. 19:882–888. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Hind CK, Carter MJ, Harris CL, Chan HT, James S and Cragg MS: Role of the pro-survival molecule Bfl-1 in melanoma. Int J Biochem Cell Biol. 59:94–102. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Xiao P, Chen Y, Jiang H, Liu YZ, Pan F, Yang TL, Tang ZH, Larsen JA, Lappe JM, Recker RR, et al: In vivo genome-wide expression study on human circulating B cells suggests a novel ESR1 and MAPK3 network for postmenopausal osteoporosis. J Bone Miner Res. 23:644–654. 2008. View Article : Google Scholar : PubMed/NCBI

36 

Lin J and Lei Z: Chromatin immunoprecipitation with estrogen receptor 1 and the promoter of Greb1 in TM4 sertoli cells. Methods Mol Biol. 1366:67–77. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Tian K, Qi W, Yan Q, Zhang F, Song D, Zhang H and Lv M: Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma. Oncol Rep 38: 2335-2342, 2017.
APA
Tian, K., Qi, W., Yan, Q., Zhang, F., Song, D., Zhang, H., & Lv, M. (2017). Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma. Oncology Reports, 38, 2335-2342. https://doi.org/10.3892/or.2017.5914
MLA
Tian, K., Qi, W., Yan, Q., Zhang, F., Song, D., Zhang, H., Lv, M."Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma". Oncology Reports 38.4 (2017): 2335-2342.
Chicago
Tian, K., Qi, W., Yan, Q., Zhang, F., Song, D., Zhang, H., Lv, M."Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma". Oncology Reports 38, no. 4 (2017): 2335-2342. https://doi.org/10.3892/or.2017.5914
Copy and paste a formatted citation
x
Spandidos Publications style
Tian K, Qi W, Yan Q, Zhang F, Song D, Zhang H and Lv M: Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma. Oncol Rep 38: 2335-2342, 2017.
APA
Tian, K., Qi, W., Yan, Q., Zhang, F., Song, D., Zhang, H., & Lv, M. (2017). Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma. Oncology Reports, 38, 2335-2342. https://doi.org/10.3892/or.2017.5914
MLA
Tian, K., Qi, W., Yan, Q., Zhang, F., Song, D., Zhang, H., Lv, M."Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma". Oncology Reports 38.4 (2017): 2335-2342.
Chicago
Tian, K., Qi, W., Yan, Q., Zhang, F., Song, D., Zhang, H., Lv, M."Combined analysis of ChIP-seq and gene microarray datasets identify the E2-mediated genes in ERα-dependent manner in osteosarcoma". Oncology Reports 38, no. 4 (2017): 2335-2342. https://doi.org/10.3892/or.2017.5914
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team